COMUNICATO STAMPA - CONTENUTO PROMOZIONALE
CHENGDU, China, Aug. 21, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026, with total revenue of RMB617 million. Core product Kangyueda generated sales of RMB393 million, up 132% YoY, supported by
In July 2026, Kangyueda was included in the National Essential Medicines List (effective Sept 1), accelerating penetration into county-level and primary care markets. Pipeline Momentum: Stapokibart's NDA for adolescent AD and prurigo nodularis were accepted; Phase III trials in pediatric AD and adolescent SAR are ongoing.
CM336 (BCMA x CD3 bispecific antibody), on June 5, NewCo partner Ouro Medicines was acquired by Gilead and Lakefront. Keymed received an upfront payment of US$257 million, with up to US$70 million in additional milestones, and retains eligibility for up to US$610 million in future milestones and tiered royalties. Lakefront will lead Phase I/II studies of CM336/OM336, while Gilead handles registrational and late‑stage trials and holds exclusive global commercialization rights (ex‑Greater China).
CMG901/AZD0901 (CLDN18.2 ADC), global Phase III for first‑line gastric cancer enrolled first patient in early 2026; perioperative study is in Phase II, with expansion into biliary and pancreatic cancers.
CM355/PRO-203 (CD20 x CD3), dosed first SSc patient in June and will initiate other B‑cell autoimmune studies in 2026.
CM512 (TSLP/IL-13 bispecific antibody) – the world's first long‑acting dual inhibitor with a 70‑day half‑life – met all Phase II endpoints in CRSwNP, showing rapid polyp shrinkage and six‑month single‑injection efficacy; Phase III initiated. Indications include asthma, COPD, AD, allergic rhinitis, and CSU.
CM336 (BCMA x CD3bispecific antibody): in autoimmune diseases, Phase II for light‑chain amyloidosis is enrolling; breakthrough therapy designation granted in May. Phase I/II for autoimmune cytopenias completed Phase I enrollment; Phase Ib for Sjögren's syndrome started in July. In oncology, IND for CM336 plus CM313 (CD38 mAb) in second‑line RRMM was accepted.
Keymed operates 6 integrated platforms, with Chengdu production capacity of 21,800L (plus 24,000L stainless steel lines soon operational). As of June 30, 1,768 full‑time employees, including 500 in commercial and 420 in R&D/clinical.
Standing at its tenth anniversary, Keymed continues its patient‑centric, dual‑engine strategy to accelerate global innovation and deliver sustainable value.
View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-2026-h1-results-and-business-updates-302857235.html
Copyright 2026 PR Newswire. All Rights Reserved.
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall'ente che lo emette. L'Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi
